BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:01 PM
 | 
Feb 01, 2008
 |  BC Extra  |  Company News

Europe approves label change for Galvus

The EC approved a revision to the prescribing information for diabetes drug Galvus vildagliptin from Novartis (NYSE:NVS; SWX:NOVN) to include use with a sulfonylurea at a 50 mg...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >